Press release
BioFocus enters collaboration with Michael J. Fox Foundation
BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.“We are delighted to have the opportunity to support The Michael J. Fox Foundation in its development of improved therapies for those living with Parkinson’s,” said Dr Kate Hilyard, VP Biological Sciences. “The collaboration will utilize BioFocus' biology platform that delivers drug discovery solutions through its experienced teams and state-of-the-art technologies”.
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest private funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding over $240 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
About BioFocus
BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery. BioFocus’ offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools. As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries. More information at: www.biofocus.com.
BioFocus® and SilenceSelect® are trademarks of Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.
Alto Marketing
Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL
Product enquiries
BioFocus:
Kate Hilyard
Tel: +44 1799 533 500
Email: kate.hilyard@glpg.com
Media enquiries
Alto Marketing Limited:
Paul Avery
Tel: +44 1489 557 672
Email: paulavery@alto-marketing.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BioFocus enters collaboration with Michael J. Fox Foundation here
News-ID: 183941 • Views: …
More Releases from BioFocus
Argenta and BioFocus announce two-year extension of drug discovery collaboration …
Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).
This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery…
BioFocus and InterMed Discovery announce Marketing Collaboration
BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.
Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of…
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.
BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a…
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.
“We are delighted to support Astellas Pharma…
More Releases for Parkinson’s
Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082
The report provides a comprehensive analysis of company profiles listed below:
- Teva
- Roche
- Prothena
- Acorda…
Parkinson’s Disease Treatment Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Parkinson’s Disease Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Parkinson’s Disease Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Parkinson’s Disease Treatment with respect…
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds…
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that…
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports.
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,…
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent.
Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial…
